Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Analysts at HC Wainwright dropped their FY2024 EPS estimates for Merus Labs International in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst A. He now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.24) for the year, down from their prior estimate of ($0.20). HC Wainwright also issued estimates for Merus Labs International’s FY2027 earnings at ($0.25) EPS.
Merus Labs International Price Performance
Merus Labs International has a 52 week low of C$0.95 and a 52 week high of C$1.76. The business’s 50-day simple moving average is C$1.65.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Further Reading
- Five stocks we like better than Merus Labs International
- Want to Profit on the Downtrend? Downtrends, Explained.
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- What is Forex and How Does it Work?
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
